Elicio Therapeutics (ELTX) SEC Filings: History & Chart

Elicio Therapeutics, Inc.(ELTX)

Biotechnology · Boston, MA

$1.88-0.04 (-2.08%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Boston, MA

33 employees

elicio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert T. Connelly

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 14, 2026	Sep 14, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
SC 13G	Jul 16, 2026	Jul 16, 2026	View filing
SC 13G/A	Jul 8, 2026	Jul 8, 2026	View filing
424B5	Jul 2, 2026	Jul 2, 2026	View filing
8-K	Jul 2, 2026	Jul 2, 2026	View filing
8-K	Jun 24, 2026	Jun 24, 2026	View filing
8-K	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
10-Q	May 11, 2026	May 11, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
10-K/A	Apr 29, 2026	Apr 29, 2026	View filing
EFFECT	Mar 16, 2026	Mar 17, 2026	View filing
8-K	Mar 16, 2026	Mar 16, 2026	View filing
424B5	Mar 16, 2026	Mar 16, 2026	View filing
S-8	Mar 12, 2026	Mar 12, 2026	View filing
S-3/A	Mar 12, 2026	Mar 12, 2026	View filing
10-K	Mar 12, 2026	Mar 12, 2026	View filing

SEC Filings

Recent Filings